Added to YB: 2025-06-06
Pitch date: 2025-06-04
NVO [bullish]
Novo Nordisk A/S
-35.88%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 479.40
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Best Buys For June: Novo Nordisk A/S
NVO: Mission-driven diabetes & obesity leader with 40%+ margins, 20+ years dividends. Semaglutide (Ozempic/Wegovy) leads $100B+ obesity market with first-mover advantage. Deep pipeline extends to cardiovascular, kidney, NASH & Alzheimer's. Global reach with tiered pricing. Robust FCF, low debt, steady buybacks, high ROIC.
Read full article (2 min)